Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.58 |
| ▸ | F2 | P00734 | 2/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13632180 | 1.00 | F10 (0.58) | F10F2ABCB11ST14PTGS2 | |
| SCHEMBL13632181 | 0.91 | F10 (0.57) | F10F2ABCB11ST14 | |
| SCHEMBL4516592 | 0.91 | F10 (0.57) | F10F2ABCB11ST14 | |
| SCHEMBL4509377 | 0.81 | F10 (0.54) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4500387 | 0.81 | F10 (0.54) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13632178 | 0.81 | F10 (0.54) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4516746 | 0.79 | F10 (0.54) | F10F2ABCB11ST14CYP3A4 | |
| SCHEMBL5631625 | 0.79 | F10 (0.65) | F10F2ABCB11ST14 | |
| SCHEMBL5432804 | 0.79 | F10 (0.65) | F10F2ABCB11ST14 | |
| SCHEMBL4504965 | 0.78 | F10 (0.53) | F10F2ABCB11ST14CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615549-B2 | Substituted pyrrolidinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-10 | — | — | US | disclosed |
| US-20060142263-A1 | NEW SUBSTITUTED PYRROLIDINONES, THEIR MANUFACTURE AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142263-A1 | NEW SUBSTITUTED PYRROLIDINONES, THEIR MANUFACTURE AND THEIR USE AS MEDICAMENTS | PYCR1, OAT, UROD | F10 814/4885F2 405/4885ABCB11 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.